Related Experiment Video
Updated: Jun 3, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Phosphodiesterase-5 Inhibitors in Neurodegenerative Diseases: A Path to Cognitive Rescue
Madhumitha Shankar1, Prashant Tiwari1, Sonal Dubey1
1College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru, Karnataka, 562112, India.
Current Protein & Peptide Science
|June 2, 2026
Summary
Phosphodiesterase type 5 inhibitors (PDE5-Is) show neuroprotective potential for Alzheimer's, Parkinson's, and MS. These agents modulate key pathways, offering a promising therapeutic avenue for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Phosphodiesterase type 5 inhibitors (PDE5-Is), initially for cardiovascular issues, are explored for neurodegenerative diseases like Alzheimer's (AD), Parkinson's (PD), and multiple sclerosis (MS).
- PDE5-Is modulate intracellular pathways, including nitric oxide synthase (NOS) expression, cyclic guanosine monophosphate (cGMP) levels, and protein kinase G (PKG) activation, impacting synaptic plasticity and neuronal survival.
Purpose of the Study:
- To review the neuroprotective potential and therapeutic applications of PDE5 inhibitors in neurodegenerative diseases.
- To explore the mechanisms underlying PDE5-Is' effects on neuroinflammation, oxidative stress, and neuronal apoptosis relevant to AD, PD, and MS.
Main Methods:
- Review of preclinical studies investigating PDE5-Is in animal models of AD, PD, and MS.
- Analysis of research on PDE5-Is' impact on molecular targets and pathological hallmarks of neurodegeneration.
- Examination of emerging evidence regarding PDE5-Is in cerebral ischemia.
Main Results:
- Preclinical studies indicate PDE5-Is reduce neuroinflammation, enhance neurogenesis, and improve cognitive function in models of AD, PD, and MS.
- PDE5-Is show promise in mitigating AD-specific pathologies (amyloid-beta, tau), improving dopamine signaling in PD, and exerting immunomodulatory effects in MS.
- Emerging research suggests PDE5-Is offer neuroprotection against ischemic injury by enhancing cerebral blood flow and reducing excitotoxicity.
Conclusions:
- PDE5 inhibitors possess multifaceted mechanisms for treating neurodegenerative diseases, addressing key pathologies like neuroinflammation and apoptosis.
- Despite promising preclinical data, clinical translation requires further research into blood-brain barrier penetration, dosing, and long-term safety.
- PDE5-Is represent a novel therapeutic strategy warranting continued investigation for neurodegenerative disorders.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...